Get started

Biotech

Bullish Charts - Acacia Buys Stake in 19 CompaniesAcacia Research Corporation, together with its subsidiaries, invests in intellectual property and related absolute return assets; and engages in the licensing and enforcement of patented technologies. It assists patent owners with the prosecution and development of their patent portfolios; protection of their patented inventions from unauthorized use; generation of licensing revenue from users of their patented technologies; and enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The company owns or controls the rights to various patent portfolios, which include U.S. patents and foreign counterparts covering technologies used in a range of industries. It has executed approximately 1,570 license agreements, and approximately 200 patent portfolio licensing and enforcement programs. Acacia Research Corporation was founded in 1993 and is headquartered in Irvine, California. On 6/5/2020, Acacia agreed to acquire a portfolio of Life Science Assets for $283 Million The transaction allows Acacia to purchase shares in up to 19 public and private life sciences companies. Lets see where this one goes now. Looks undervalued at current levels. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ACTGLong
by HotCharts
BNR is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea Burning Rock Biotech Limited focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology. The share price is rising and gonna continue this trend today. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price today. So I opened a long position from $24,54; take-profit — $32,74; stop-loss — $21,82. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:BNRLong
by KozakHlib
RNA is giving a GREAT IPO LONG opportunity today IPO intraday trading strategy idea Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. The share price is rising and gonna continue this trend today. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price today. So I opened a long position from $28,4; take-profit — $38,12 stop-loss — $25,16 Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:RNALong
by KozakHlib
1
GBIO is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea Generation Bio is an innovative genetic medicine company creating a new class of gene therapy. The share price is rising and gonna continue this trend today. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price today. So I opened a long position from $23,31; take-profit — $28,53; stop-loss — $21,57. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:GBIOLong
by KozakHlib
$ATOS can rise in the next daysContextual immersion trading strategy idea. Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The share price rose after announcing the availability of the CEO's 158-page book "Your COVID-19 Survival Manual: A Physician's Guide to Keep You and Your Family Healthy During the Pandemic and Beyond" The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $3,21; stop-loss — $3,08. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ATOSLong
by KozakHlib
$NTLA can rise in the next daysContextual immersion trading strategy idea. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The share price rose after the company announced an expansion of its partnership with Regeneron Pharmaceuticals (REGN). The pair will jointly develop drug candidates to treat hereditary blood disorders hemophilia A and hemophilia B. Additionally, Regeneron Pharmaceuticals will gain rights to develop drug candidates using both in vivo (inside the body) and ex vivo (outside the body) drug candidates and delivery tools developed by Intellia Therapeutics — www.fool.com The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $22,24; stop-loss — $21,25. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:NTLALong
by KozakHlib
ONTX - Could Breakout, How Far?All, ONTX is overdue for a takeoff. Today it is at +30% premarket, but this is why you do TA and watch Volume at open. It will gap above both blue lines for support and .44/.45 are aboth huge support lines. My theory is simple it may sell off around .53. However, I would hold and wait for the rally at .39 or .44 to push back up to .70-.75. The question there becomes will it break or fail that area on second re test? ALSO FIRST THING IS FIRST WATCH THE MARKET BEFORE YOU BUY ANY STOCK. S&P / NASDAQ AND WATCH VOLUME ON INVERSE S&P ETFS.
OLong
by DigitalData
ABBV an Entry Point into the Wild World of BiotechBiotechnology and pharmaceutical companies have been quickly cycling through overbought and oversold. The problem has been so problematic that Sorrento Therapeutics had to specifically claim they were not a “pump and dump” scheme. Any whisper of a "cure" for Covid-19 has investors rushing to the entrance and quickly fleeing after results are what they had expected (an image of people rushing toward the exit and getting stuck in door comes to my mind). People who know the biotech sector have been cautiously watching the spectacle and trying to avoid getting trampled in a stampede. To be clear: your average investor is getting burned in the vaccine-hunt game. AbbVie "ABBV" is (and has been) a reliable pharmaceutical and biotechnology company for some time. The company is known for its generous dividend – previously at a yield of 5.20%. The company has a robust balance sheet with a Quick Ratio of 3.03 and a Current Ratio of 3.14. In the world of biotech, research and development is everything. ABBV pipeline is stacked with potential drug candidates many of which are in Phase 3 of development according to AbbVie’s investor relations brochure. From a technical analysis standpoint, the moving averages appear to be moving toward a positive crossover – EMA10 = 91.00, EMA20 = 90.88 EMA25 = 90.87. The stock does not look overbought or oversold according to the Stoch RSI and Money Flow Indicator. However, the MACD indicator shows that there may be a further swing downward before moving into positive territory. Finally, the linear regression model is one of the few biotechnology companies that is not inverse or appears caught in a sideway pattern. LONG ABBV purchased today (06-02-2020) @ 90.86.
NYSE:ABBVLong
by luminaryfi
6